MCID: RHN004
MIFTS: 57

Rhinitis

Categories: Bone diseases, Respiratory diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Rhinitis

MalaCards integrated aliases for Rhinitis:

Name: Rhinitis 11 28 53 43 14 16 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:4483
MeSH 43 D012220
NCIt 49 C34986
SNOMED-CT 68 70076002
UMLS 71 C0035455

Summaries for Rhinitis

Disease Ontology: 11 A upper respiratory infectious disease which involves irritation and inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants. The inflammation results in generation of excessive amounts of mucus leading to runny nose, as well as nasal congestion and post-nasal drip.

MalaCards based summary: Rhinitis is related to chronic rhinitis and vasomotor rhinitis, and has symptoms including rhinorrhea, sneezing and sinus congestion. An important gene associated with Rhinitis is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and t cells, and related phenotypes are Reduced mammosphere formation and immune system

Wikipedia: 75 Rhinitis, also known as coryza, is irritation and inflammation of the mucous membrane inside the nose.... more...

Related Diseases for Rhinitis

Diseases in the Rhinitis family:

Chronic Rhinitis

Diseases related to Rhinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 chronic rhinitis 33.6 RNASE3 IL5 IL4 IL13 HRH1
2 vasomotor rhinitis 32.8 RNASE3 KNG1 IL5 IL4 IL13 HRH1
3 ige responsiveness, atopic 32.7 RNASE3 IL5 IL4R IL4 IL13 IGHE
4 common cold 32.5 RNASE3 IL5 IL4 IL13 ICAM1 CXCL8
5 pollen allergy 32.5 IL5 IL4 IL13
6 allergic rhinitis 32.4 VCAM1 RNASE3 NR3C1 NGF KNG1 IL5
7 allergic conjunctivitis 32.1 RNASE3 IL5 IL4 IL13 IGHE HRH1
8 giant papillary conjunctivitis 31.9 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
9 allergic asthma 31.8 VCAM1 RNASE3 IL5 IL4R IL4 IL13
10 dermatitis 31.8 RNASE3 IL5 IL4R IL4 IL13 IGHE
11 hypereosinophilic syndrome 31.6 RNASE3 IL5 IL4 IL13 IGHE EPX
12 urticaria 31.6 RNASE3 IL5 IL4 IL13 IGHE HRH1
13 conjunctivitis 31.5 RNASE3 IL5 IL4 IL13 IGHE ICAM1
14 occupational asthma 31.5 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
15 dermatitis, atopic 31.5 VCAM1 RNASE3 NGF IL5 IL4R IL4
16 adenoid hypertrophy 31.3 IL5 IL4 CYSLTR1 CXCL8
17 otitis media 31.3 RNASE3 IL5 IL4 IL13 IGHE ICAM1
18 food allergy 31.3 RNASE3 IL5 IL4R IL4 IL13 IGHE
19 childhood-onset asthma 31.2 RNASE3 IL5 IL4R IL4 IL13 IGHE
20 chronic urticaria 31.2 RNASE3 IL5 IGHE HRH1
21 sleep apnea 31.2 VCAM1 ICAM1 CXCL8
22 aspergillosis 31.1 IL5 IL4 EPX CXCL8 CCL5
23 apnea, obstructive sleep 31.1 POMC ICAM1 CXCL8
24 viral infectious disease 31.1 IL4 IL13 ICAM1 CXCL8 CCL5
25 allergic disease 31.1 VCAM1 RNASE3 KNG1 IL5 IL4R IL4
26 gastroesophageal reflux 31.1 IL5 IL4 CXCL8 CCL11
27 bronchitis 31.1 RNASE3 IL5 IL4 IL13 IGHE CXCL8
28 respiratory allergy 31.0 RNASE3 IL5 IL4R IL4 IL13 HRH1
29 chronic spontaneous urticaria 31.0 KNG1 IL5 IL4 IL13 HRH1
30 drug allergy 31.0 IL5 IL4 IL13 IGHE
31 pulmonary disease, chronic obstructive 31.0 RNASE3 NR3C1 IL13 CXCL8 CCL5 CCL11
32 proteasome-associated autoinflammatory syndrome 1 30.9 VCAM1 RNASE3 IL5 IL4 IL13 IGHE
33 contact dermatitis 30.9 RNASE3 IL5 IL4 IL13 CXCL8 CCL11
34 exercise-induced bronchoconstriction 30.8 RNASE3 IL5 IL4 IL13 IGHE CYSLTR1
35 intermittent asthma 30.8 RNASE3 IL5 IL4 IL13 CYSLTR1 CXCL8
36 leprosy 3 30.8 IL5 IL4 IL13 CXCL8
37 respiratory failure 30.8 RNASE3 KNG1 IL5 IL4 IL13 IGHE
38 lung disease 30.8 RNASE3 IL5 IL13 ICAM1 CXCL8 CCL5
39 respiratory syncytial virus infectious disease 30.7 IL5 IL13 CCL5
40 asthma 30.7 VCAM1 RNASE3 POMC NR3C1 KNG1 IL5
41 autoimmune disease 30.7 VCAM1 IL5 IL4 IL13 ICAM1 CCL5
42 chlamydia 30.7 IL5 IL4 CXCL8
43 ascaris lumbricoides infection 30.6 IL5 IL4 IL13
44 thunderstorm triggered asthma 30.6 RNASE3 IL5 IL4 IL13
45 cough variant asthma 30.6 RNASE3 IL5 IL4 IL13
46 peanut allergy 30.6 IL5 IL4 IL13 IGHE
47 chronic fatigue syndrome 30.6 POMC NR3C1 IL4 CXCL8
48 middle ear disease 30.6 IL5 IL4 CXCL8
49 candidiasis 30.6 IL5 IL4 CXCL8
50 fibromyalgia 30.6 POMC NGF IL4 CXCL8

Graphical network of the top 20 diseases related to Rhinitis:



Diseases related to Rhinitis

Symptoms & Phenotypes for Rhinitis

UMLS symptoms related to Rhinitis:


rhinorrhea; sneezing; sinus congestion; nasal congestion (finding); nasal irritation; posterior rhinorrhea

GenomeRNAi Phenotypes related to Rhinitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 C5AR1 CXCL8 IL4R IL5 NR3C1 POMC

MGI Mouse Phenotypes related to Rhinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.03 C5AR1 CCL11 CCL5 CYSLTR1 EPX HRH1
2 no phenotypic analysis MP:0003012 9.8 IGHE IL13 IL4 NGF NR3C1 POMC
3 respiratory system MP:0005388 9.56 CCL11 CYSLTR1 FOXJ1 IL13 IL4 IL4R
4 hematopoietic system MP:0005397 9.47 C5AR1 CCL11 CCL5 EPX HRH1 ICAM1

Drugs & Therapeutics for Rhinitis

Drugs for Rhinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
4
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
5
Cetirizine Approved Phase 4 83881-51-0 2678
6
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
7
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
8
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
9
Omalizumab Approved, Investigational Phase 4 242138-07-4
10
Terfenadine Approved, Withdrawn Phase 4 50679-08-8 5405
11
Salbutamol Approved, Vet_approved Phase 4 18559-94-9 2083
12
Ethanol Approved Phase 4 64-17-5 702
13
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
14
Prazosin Approved Phase 4 19216-56-9 4893
15
Doxazosin Approved Phase 4 74191-85-8 3157
16
Calcium carbonate Approved, Investigational Phase 4 471-34-1
17
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
18
Adenosine Approved, Investigational Phase 4 58-61-7 60961
19
Theophylline Approved Phase 4 58-55-9 2153
20
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
21
Wormwood Approved, Experimental Phase 4
22
Emedastine Approved Phase 4 87233-61-2 3219
23
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350 164522
24
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
25
Montelukast Approved Phase 4 158966-92-8 5281040
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27
Resveratrol Investigational Phase 4 501-36-0 445154
28
Tranilast Investigational Phase 4 53902-12-8 5282230
29 Purple Butterbur Phase 4
30 Proton Pump Inhibitors Phase 4
31 Cholinergic Antagonists Phase 4
32 Cholinergic Agents Phase 4
33
Ethylene Phase 4 74-85-1 6325
34
Salmeterol Xinafoate Phase 4 94749-08-3
35 Epinephryl borate Phase 4
36
Beclomethasone Phase 4 2308 20469
37 Phosphodiesterase Inhibitors Phase 4
38 Interleukin-12 Phase 4
39 Mitogens Phase 4
40 Adrenergic beta-Agonists Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Acidophilus Phase 4
43 Fluticasone-Salmeterol Drug Combination Phase 4
44 Lubricant Eye Drops Phase 4
45 Calcium, Dietary Phase 4
46 Tocolytic Agents Phase 4
47 Adrenergic Antagonists Phase 4
48 Adrenergic alpha-Antagonists Phase 4
49 Adrenergic alpha-1 Receptor Antagonists Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1130)
# Name Status NCT ID Phase Drugs
1 Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on "Seal" to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
2 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
3 A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis Unknown status NCT01062139 Phase 4 Xarlin (Levocetirizine);Cosalin (Petasites hybridus CO2 extract)
4 Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status NCT02402465 Phase 4 Placebo;Fluticasone propionate;Fluticasone/Azelastine nasal spray
5 Randomized Controlled Trial Evaluating Combination Rupatadine and Fluticasone Propionate Compared to Azelastine Hydrochloride and Fluticasone Propionate in Treating Allergic Rhinitis Unknown status NCT04601324 Phase 4 Fluticasone Propionate;Azelastine hydrochloride and fluticasone propionate;Rupatadine
6 SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
7 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
8 AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
9 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy Unknown status NCT01785394 Phase 4 5 grass allergen extract
12 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794599 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
13 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794846 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
14 Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR) Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
15 Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis Completed NCT00794495 Phase 4 Desloratadine 5 mg (Clarinex);Cetirizine (Zyrtec)
16 Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I) Completed NCT00637611 Phase 4 Fexofenadine HCl
17 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
18 A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius. Completed NCT00805584 Phase 4 desloratadine
19 A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis. Completed NCT00741897 Phase 4 Fexofenadine
20 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Completed NCT02014623 Phase 4 Control
21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis. Completed NCT00641212 Phase 4 Budesonide;Placebo
22 Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Completed NCT00637455 Phase 4 fexofenadine HCl
23 Randomized, Double-blind, Placebo-controlled Study to Measure 2L®ALERG (Homeopathic Drug) Efficacy on Symptoms of Allergic Rhinitis and Allergic Rhinoconjunctivitis in Patients With a Seasonal Allergy to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
24 Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis Completed NCT00789555 Phase 4 Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
25 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783146 Phase 4 desloratadine;fexofenadine;placebo
26 Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine Completed NCT03004131 Phase 4 Azelastine hydrochloride + fluticasone propionate nasal spray;Placebos;fluticasone propionate nasal spray + loratadine
27 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
28 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
29 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00794248 Phase 4 desloratadine 5 mg;fexofenadine
30 A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) Completed NCT00783211 Phase 4 desloratadine;fexofenadine;placebo
31 Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites Completed NCT00521131 Phase 4 Levocetirizine dihydrochloride
32 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis Completed NCT00682643 Phase 4 fluticasone furoate nasal spray;vehicle placebo nasal spray
33 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity Completed NCT00848965 Phase 4 Fluticasone propionate;Placebo
34 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00794768 Phase 4 desloratadine 5 mg;fexofenadine
35 Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis Completed NCT00783133 Phase 4 Desloratadine 5 mg;fexofenadine
36 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
37 Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
38 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
39 Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU) Completed NCT04652245 Phase 4 Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3;Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5;Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5;Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3
40 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
41 Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis Completed NCT00822406 Phase 4 homeopathic medicine;placebo
42 Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients Completed NCT00730912 Phase 4 loratadine
43 A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis Completed NCT00539006 Phase 4 FPNS;FFNS;placebo FPNS;placebo FFNS
44 A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis Completed NCT00519636 Phase 4 FPNS;FFNS;placebo FFNS;placebo FPNS
45 A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
46 A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
47 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
48 A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
49 A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen Completed NCT00867191 Phase 4 Placebo;Desloratadine
50 Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy Completed NCT00806754 Phase 4 Ciclesonide nasal spray + placebo Azelastine;Ciclesonide nasal spray + Azelastine

Search NIH Clinical Center for Rhinitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ephedra vulgaris preparation
Ephedrine
Ephedrine hydrochloride
Ephedrine sulfate
EPHEDRINE TANNATE
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Naphazoline
Naphazoline Hydrochloride
Oxymetazoline
Oxymetazoline hydrochloride
Phenylpropanolamine

Cochrane evidence based reviews: rhinitis

Genetic Tests for Rhinitis

Genetic tests related to Rhinitis:

# Genetic test Affiliating Genes
1 Rhinitis 28

Anatomical Context for Rhinitis

Organs/tissues related to Rhinitis:

MalaCards : Eye, Skin, T Cells, Pituitary, Lung, Whole Blood, Brain

Publications for Rhinitis

Articles related to Rhinitis:

(show top 50) (show all 29907)
# Title Authors PMID Year
1
The role of mast cell-derived secreted phospholipases A2 in respiratory allergy. 53 62
20219624 2010
2
[Evaluating total serum IgE levels and peripheral eosinophil count in asthma and rhinitis]. 53 62
20502102 2010
3
Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. 53 62
19758373 2010
4
Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. 53 62
19796796 2009
5
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. 53 62
18948425 2009
6
Association of single nucleotide polymorphisms in the eosinophil peroxidase gene with allergic rhinitis in the Czech population. 53 62
19439985 2009
7
Advances in upper airway diseases and allergen immunotherapy in 2007. 53 62
18694591 2008
8
Rhinitis and onset of asthma: a longitudinal population-based study. 53 62
18805333 2008
9
Change in prevalence of atopic dermatitis between 1986 and 2001 among children. 53 62
18702887 2008
10
Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. 53 62
18312533 2008
11
Recent progress in allergen immunotherapy. 53 62
18319521 2008
12
Patterns of GATA3 and IL13 gene polymorphisms associated with childhood rhinitis and atopy in a birth cohort. 53 62
18037162 2008
13
Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study. 53 62
17822449 2007
14
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. 53 62
17886253 2007
15
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. 53 62
19075985 2007
16
Anti-IgE in allergic asthma and rhinitis: an update. 53 62
17961096 2007
17
[Clinical observation on treatment of children's mild continuous asthma by Fangchuan Mixture combined with flixotide]. 53 62
18173144 2007
18
Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma. 53 62
17967188 2007
19
Allergic asthma and rhinitis caused by household rabbit exposure: identification of serum-specific IgE and its allergens. 53 62
17982229 2007
20
Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. 53 62
17651147 2007
21
Mediators and cytokines in allergic and viral-triggered rhinitis. 53 62
17883911 2007
22
Up-regulation of protease-activated receptor 2 in allergic rhinitis. 53 62
17727088 2007
23
Cysteinyl-leukotriene levels in sputum differentiate asthma from rhinitis patients with or without bronchial hyperresponsiveness. 53 62
17581201 2007
24
Asthma and rhinitis symptoms in individuals from different socioeconomic levels in a Brazilian city. 53 62
17619568 2007
25
Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. 53 62
17337294 2007
26
What's new in paediatric sleep? 53 62
17419982 2007
27
Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis. 53 62
17298427 2007
28
Subjects with non-allergic non-infectious perennial rhinitis do not show nasal hyper-responsiveness to bradykinin. 53 62
17043856 2007
29
Uteroglobin-related protein 1 and clara cell protein in induced sputum of patients with asthma and rhinitis. 53 62
17218572 2007
30
Applicability of extracellular electrical impedance tomography in monitoring respiratory tract inflammation. 53 62
17323861 2007
31
Eosinophil cationic protein, specific IgE and IgG4 in human toxocariasis. 53 62
17125552 2006
32
Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. 53 62
16949266 2006
33
The role of allergic rhinitis in nasal responses to sudden temperature changes. 53 62
17088139 2006
34
[Is the seric eosinophil cationic protein level a valuable tool of diagnosis in clinical practice?]. 53 62
16647168 2006
35
Atopy patch testing in children with asthma and rhinitis symptoms allergic to house dust mite. 53 62
16846452 2006
36
Association between angiotensin-converting enzyme gene polymorphism and childhood allergic rhinitis in Taiwan. 53 62
16926975 2006
37
Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and persistent allergic rhinitis: relationship with disease severity. 53 62
16892784 2006
38
Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis. 53 62
16771777 2006
39
Low prevalence of the intrinsic form of atopic dermatitis among adult patients. 53 62
16629795 2006
40
Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. 53 62
16433854 2006
41
Lack of association between the IL13 variant Arg110Gln and susceptibility to cedar pollinosis in a Japanese population. 53 62
16272823 2006
42
Sensitization to blackgram in patients with bronchial asthma and rhinitis: clinical evaluation and characterization of allergens. 53 62
16364164 2006
43
[Serum eosinophil cationic protein (ECP) in patients with perennial rhinitis and atopic dermatitis, allergic to house dust mites]. 53 62
16521419 2005
44
Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study. 53 62
16232343 2005
45
Major lymphocyte populations and T-cell expression of ICAM-1 and L-selectin adhesion molecules in Kuwaitis with asthma and rhinitis. 53 62
17290844 2005
46
Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. 53 62
15990782 2005
47
Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. 53 62
15813809 2005
48
Immunological characterization of a recombinant tropomyosin from a new indoor source, Lepisma saccharina. 53 62
15836758 2005
49
Aspirin sensitivity: implications for patients with coronary artery disease. 53 62
15613671 2004
50
Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors. 53 62
15280196 2004

Variations for Rhinitis

Expression for Rhinitis

Search GEO for disease gene expression data for Rhinitis.

Pathways for Rhinitis

Pathways related to Rhinitis according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 C5AR1 CCL11 CCL5 CXCL8 EPX ICAM1
2 13.69 POMC NR3C1 NGF KNG1 IL5 HRH1
3
Show member pathways
13.6 CCL11 CCL5 CXCL8 IL13 IL4 IL4R
4
Show member pathways
13.55 POMC KNG1 HRH1 CYSLTR1 CXCL8 CCL5
5
Show member pathways
13.47 NGF IL5 IL4R IL4 IL13 ICAM1
6
Show member pathways
13.38 NGF IL5 IL4R IL4 IL13 CXCL8
7
Show member pathways
13.34 C5AR1 CCL11 CCL5 CXCL8 CYSLTR1 HRH1
8
Show member pathways
13.24 NGF IL5 IL4R IL4 IL13 CXCL8
9
Show member pathways
13.15 VCAM1 POMC IL5 IL4R IL4 IL13
10
Show member pathways
12.6 NGF IL5 IL4R IL4 IL13 CXCL8
11
Show member pathways
12.38 NR3C1 IL4 CXCL8 CCL11
12
Show member pathways
12.32 ICAM1 CXCL8 CCL5 CCL11
13
Show member pathways
12.24 IL4R IL4 IGHE CCL11
14 12.15 NR3C1 NGF IL13 CXCL8
15 12.08 NGF IL4R IL4 IL13
16 11.83 IL5 IL4 IL13 CXCL8
17 11.76 IL5 IL4 IL13
18
Show member pathways
11.67 IL5 IL4 CXCL8
19 11.66 CXCL8 IL4 IL5 NR3C1
20 11.63 CXCL8 ICAM1 VCAM1
21
Show member pathways
11.61 VCAM1 NR3C1 ICAM1 CXCL8
22 11.57 IL5 IL4R IL4 CCL11
23
Show member pathways
11.55 IL5 IL4R IL4 IL13
24 11.51 IL4R IL4 CCL5
25 11.5 ICAM1 CXCL8 CCL5
26 11.46 VCAM1 ICAM1 CXCL8
27 11.43 IL5 IL4 IL13 CXCL8 CCL5 CCL11
28 11.39 POMC NR3C1 IL5 IL4 IL13 ICAM1
29 11.38 CCL11 IL13 IL4 IL4R IL5
30 11.31 IL5 IL4R IL4
31 11.29 IL5 IL4 IL13
32 11.26 VCAM1 POMC IL4R IL4 IL13 ICAM1
33 11.24 IL5 IL4 IL13
34 11.23 VCAM1 KNG1 ICAM1
35 11.17 IL13 IL4 IL5
36 11.14 IL5 IL4 IL13 CXCL8
37 10.95 VCAM1 IL4R IL4
38 10.9 NGF IL5 IL4 IL13 CXCL8 CCL5
39 10.89 VCAM1 ICAM1
40 10.86 IL4R IL4
41 10.64 IL5 IL4R IL4 IL13
42
Show member pathways
10.36 KNG1 CXCL8

GO Terms for Rhinitis

Cellular components related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.05 RNASE3 POMC NGF KNG1 IL5 IL4R
2 extracellular space GO:0005615 9.8 CCL11 CCL5 CXCL8 EPX ICAM1 IGHE

Biological processes related to Rhinitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.23 POMC NR3C1 IL5 IL4R IL4 IL13
2 cellular response to tumor necrosis factor GO:0071356 10.15 VCAM1 CXCL8 CCL5 CCL11
3 inflammatory response GO:0006954 10.06 C5AR1 CCL11 CCL5 CXCL8 HRH1 IL13
4 positive regulation of B cell proliferation GO:0030890 10.03 IL5 IL4 IL13
5 neutrophil chemotaxis GO:0030593 10.01 CXCL8 CCL5 CCL11 C5AR1
6 negative regulation of endothelial cell apoptotic process GO:2000352 10 IL4 IL13 ICAM1
7 leukocyte cell-cell adhesion GO:0007159 9.99 CCL5 ICAM1 VCAM1
8 positive regulation of immunoglobulin production GO:0002639 9.93 IL5 IL4R IL13
9 microglial cell activation GO:0001774 9.91 IL4 IL13 C5AR1
10 chronic inflammatory response GO:0002544 9.88 VCAM1 CCL11
11 T-helper 2 cell differentiation GO:0045064 9.88 IL4R IL4
12 eosinophil chemotaxis GO:0048245 9.85 CCL11 CCL5 HRH1
13 membrane to membrane docking GO:0022614 9.84 VCAM1 ICAM1
14 positive regulation of cellular biosynthetic process GO:0031328 9.8 CXCL8 CCL5
15 positive regulation of mast cell degranulation GO:0043306 9.8 IL4R IL4 IL13
16 negative regulation of complement-dependent cytotoxicity GO:1903660 9.78 IL4 IL13
17 neuroinflammatory response GO:0150076 9.74 NR3C1 IL4
18 chemotaxis GO:0006935 9.73 RNASE3 CYSLTR1 CXCL8 CCL5 CCL11 C5AR1
19 immune response GO:0006955 9.5 IL5 IL4R IL4 IL13 IGHE CXCL8

Molecular functions related to Rhinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CXCL8 CCL5 CCL11
2 cytokine activity GO:0005125 9.28 IL5 IL4 IL13 CXCL8 CCL5 CCL11

Sources for Rhinitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....